Janux Therapeutics (NASDAQ:JANX) Given "Outperform" Rating at William Blair

William Blair reaffirmed their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX - Free Report) in a research note released on Friday,RTT News reports.

JANX has been the subject of a number of other reports. Stifel Nicolaus increased their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. Leerink Partners raised their price target on Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a report on Tuesday, December 3rd. Scotiabank raised their price target on Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a report on Wednesday, December 4th. BTIG Research raised their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $89.90.

Janux Therapeutics Stock Down 8.0 %

NASDAQ:JANX traded down $4.06 during mid-day trading on Friday, reaching $46.76. 2,112,806 shares of the stock were exchanged, compared to its average volume of 1,520,717. The company has a 50 day simple moving average of $54.42 and a 200-day simple moving average of $48.18. The stock has a market capitalization of $2.45 billion, a P/E ratio of -39.97 and a beta of 3.23. Janux Therapeutics has a 1 year low of $7.79 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The firm's revenue for the quarter was down 82.6% on a year-over-year basis. As a group, research analysts predict that Janux Therapeutics will post -1.35 EPS for the current year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the firm's stock in a transaction on Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the transaction, the chief executive officer now owns 282,054 shares of the company's stock, valued at approximately $15,101,171.16. This trade represents a 8.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the firm's stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $50.02, for a total value of $92,186.86. Following the transaction, the insider now directly owns 6,371 shares of the company's stock, valued at $318,677.42. The trade was a 22.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,177 shares of company stock valued at $6,162,207 in the last ninety days. Corporate insiders own 29.40% of the company's stock.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Amalgamated Bank grew its position in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company's stock valued at $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics during the second quarter worth about $42,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after purchasing an additional 339 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Janux Therapeutics in the second quarter worth about $215,000. Finally, Chicago Partners Investment Group LLC acquired a new position in shares of Janux Therapeutics in the third quarter worth about $239,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.